Micelle-Associated Protein in Epoetin Formulations: A Risk Factor for Immunogenicity?

Author： Hermeling Suzanne   Schellekens Huub   Crommelin Daan J. A.   Jiskoot Wim  

Publisher： Springer Publishing Company

ISSN： 0724-8741

Source： Pharmaceutical Research, Vol.20, Iss.12, 2003-12, pp. : 1903-1907

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

A Risk-Benefit Assessment of Epoetin in the Management of Anaemia Associated with Cancer

By Beguin Y.  

Drug Safety, Vol. 19, Iss. 4, 1998-10 ,pp. : 269-282

Adis International

Access to resources Recommend Favorite

Minimizing the immunogenicity of protein therapeutics

By Chirino A.J.   Ary M.L.   Marshall S.A.  

Drug Discovery Today, Vol. 9, Iss. 2, 2004-01 ,pp. : 82-90

Elsevier

Access to resources Recommend Favorite

Reducing the Immunogenicity of Protein Therapeutics

By  

Current Drug Targets, Vol. 10, Iss. 2, 2009-02 ,pp. : 131-139

Bentham Science Publishers

Access to resources Recommend Favorite

Immunogenicity of meningococcal PorA formulations encapsulated in biodegradable microspheres

By Arigita C.   van den Berg J.   Wensink K.   van Steenbergen M.   Hennink W.E.   Crommelin D.J.A.   Kersten G.F.A.   Jiskoot W.  

European Journal of Pharmaceutical Sciences, Vol. 21, Iss. 2, 2004-02 ,pp. : 131-141

Elsevier

Access to resources Recommend Favorite

The use of darbepoetin-α to treat anaemia in patients with cancer is associated with lower overall costs compared with epoetin-α and epoetin-β

By  

Inpharma, Vol. 1, Iss. 1562, 2006-01 ,pp. : 4-4

Adis International

Access to resources Recommend Favorite